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Introduction
Type 2 diabetes mellitus (T2DM) is a
progressive disease characterized as
having pancreatic β-cell dysfunction,
insulin resistance and hyperglycemia
(Stephens, 2010, p. 491). T2DM affected
29.1 million Americans or 9.3% of the
population in 2012 and was the seventh
leading cause of death in the United
States in 2010 ("ADA Statistics," 2014),
with many of these patients finding it
difficult to achieve or maintain adequate
glycemic control despite making lifestyle
changes and pharmacologic interventions
(Freeman, 2007).
Disease management of T2DM
requires a comprehensive plan including
medication therapy, education and active
involvement of the patient, with the goal
of therapy to lower the A1C (Robertson,
2012). Incretin mimetics are a class of
medications available for treating
patients with T2DM; they mimic the
action of incretin hormones released
during nutrient absorption (Freeman,
2007). Patients with T2DM have an
impaired incretin response (Pratley, n.d.,
p. 8).

Incretin Effect
The incretin effect is the secretion of
insulin after ingestion of food compared
to the isoglycemic intravenous glucose
challenges (Ahren, 2013). Incretins are
peptide hormones that originate in the
gut and increase the effectiveness of
insulin secretion after meal ingestion in a
glucose-dependent manner (Campbell &
Drucker, 2013). Glucose-dependent
insulinotropic polypeptide (GIP) and
glucagon-like-peptide-1 (GLP-1) are the
two dominant incretin hormones and are
responsible for the so-called “incretin
effect” (Campbell & Drucker, 2013, p.
819). GLP-1 and GIP play an essential
role in maintaining normal glucosehomeostasis and in particular
postprandial glucose levels ("Incretin
physiology," 2014). Incretin therapy is
associated with a low risk of adverse
events such as hypoglycemia (Ahren,
2013).

GIP
GIP is a 42 amino acid peptide
(Drucker, 2006, p. 153) secreted from
duodenum K-cells in the proximal small
intestine and is transported through the
blood (Pratley, n.d., p. 7). Nutrient
intake stimulates GIP production; GIP
levels are low in the fasted state and will
rise within minutes of food consumption
(Drucker, 2006). GIP has direct effects
on insulin secretion that are mediated
through a specific receptor for GIP on β
cells (Pratley, n.d., p. 8). GIP has a short
half-life of seven minutes (Cornell,
2013), and is eliminated from the
circulation via the kidneys (Drucker,
2006). GIP is rapidly inactivated by
dipeptidyl peptidase-4 (DPP-4), an
exopeptidase (Drucker, 2013).
According to Drucker (2006), GIP does
not appear to be important for control of
fasting glucose.

GLP-1
GLP-1 is produced in
enteroendocrine cells in the distal small
bowel and colon from L-cells (Drucker,
2006, p. 153) and binds to a G-protein
coupled receptor in the endocrine
pancreas (Burgmaier, Heinrich, & Marx,
2012). Via stimulation of adenylyl
cyclase and cyclic adenosine
monophosphate (cAMP) production
(Burgmaier et al., 2012, p. 290), GLP-1
increases insulin secretion from
pancreatic β cells and inhibits glucagon
secretion from α cells, increases insulin
synthesis, confers glucose sensitivity to
glucose-resistant β cells, stimulates β
cell proliferation and regeneration, and
inhibits β cell apoptosis (Campbell &
Drucker, 2013). GLP-1 plasma levels
rise within minutes after food intake and
has a short half-life of two minutes and
like GIP is degraded rapidly by DPP-4
and excreted via the kidneys (Drucker,
2013). GLP-1 lowers blood sugar levels
and body weight by inhibiting appetite
by enhancing satiety through its
hypothalamic action and by slowing
gastric emptying, which results in a
decreased influx of glucose into the
circulation (Pratley, n.d., p. 8).

DPP-4
According to Drucker (2006, p. 154),
both GLP-1 and GIP stimulate glucosedependent insulin secretion via
activation of their specific G proteincoupled receptors expressed directly on
islet β cells. Both hormones stimulate
insulin gene transcription, increase
pancreatic β cell mass and protect
against β cell apoptosis (Vilsboll & Knop,
2014, p. 2).
Incretin-based therapies are used as
add-on therapy to conventional T2DM
treatment improving glycemic control
and is generally well tolerated (Capaldi,
2012). Two classes of incretin-based
therapies are DPP-4 inhibitors and GLP1 receptor agonists.
DPP-4 is the key enzyme responsible for
inactivating GIP and GLP-1 and exists in
two principal forms: a membrane
anchored, largely extracellular protein
capable of stimulation of intracellular
signal transduction pathways
independent of its enzymatic activity,
and a circulating soluble enzyme which
retains enzymatic activity (Drucker,
2006, p. 160). According to Drucker
(2006), genetic evidence supports an
essential role of DPP-4 in the control of
glucose homeostasis.
DPP-4 inhibitors block the action of
the enzyme that degrades GLP-1 by
slowing the rapid degradation of GLP-1
to the metabolite GLP-1 (9-36) amide
(Burgmaier et al., 2012, p. 290). DPP-4
inhibitors also decrease the degradation
of other peptides that are substrates to
DPP-4, including GIP and a variety of
chemokines (Burgmaier et al., 2012, p.
290). According to Capaldi (2012),
GLP-1 receptor agonists and DPP-4
inhibitors reduce glucose levels with low
risk of hypoglycemia and GLP-1 receptor
agonists are associated with weight loss,
whereas DPP-4 inhibitors are weight
neutral (Capaldi, 2012). DPP-4
inhibitors are rapidly absorbed and
excreted by the kidneys; therefore renal
function should be assessed before their
use (Aye & Jennings, 2009, p. 197).

Implication for
Nursing Care
GLP-1 receptor agonists are longacting which make them resistant to GLP1 inactivation by DPP-4 (Stephens,
2010). According to Capaldi (2012), selfmonitoring of blood glucose is not
needed to adjust the dose of the agent
prescribed since GLP-1 action is glucosedependent.
GLP-1 receptor agonists should be
avoided in patients with gastroparesis,
and patients need educated that nausea
is most often transient, and they should
be counseled to eat smaller meals
(Williams & Prasad-Reddy, 2012, p. 371).
Hypersensitivity reactions exist for DPP4 inhibitors: anaphylaxis, angioedema,
exfoliative skin conditions, and bronchial
hyperreactivity. Angioedema was the
most commonly reported
hypersensitivity reactions of the DPP-4
inhibitors (Williams & Prasad-Reddy,
2012, p. 371). DPP-4 inhibitor-induced
angioedema is related to reduced DPP-4
enzymatic activity and inhibited
degradation of proinflammatory
bradykinins and substance P (Williams &
Prasad-Reddy, 2012, p. 371). Pancreatitis
is listed as a precaution for GLP-1
agonists and DPP-4 inhibitors (Williams
& Prasad-Reddy, 2012). GLP-1 agonists
may prove to have a cardioprotective
function that is both receptor-dependent
and receptor-independent. Binding of
the GLP-1 receptor in the myocardium
stimulates an increase of inotropic action
(Williams & Prasad-Reddy, 2012, p. 372).
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